Senseera develops the GEM BIOMARKERS™ liquid‑biopsy platform powered by cfChIP‑seq technology to decode cell‑specific gene expression and cell states from blood draws. Its platform is built on decades of research led by Prof. Nir Friedman and validated in Nature Biotechnology, supported by data from over 20,000 human samples. Senseera targets diagnostics and monitoring across oncology, immunology, metabolic diseases and a dedicated liver‑diseases pipeline addressing MASLD/MASH, transplant rejection and hepatocellular carcinoma. The company plans to accelerate market entry of a next‑generation transplant rejection test, advance clinical trials, and expand partnerships with global biopharma. The technology aims to provide biopsy‑level precision non‑invasively to improve early detection, patient monitoring, and to support drug development and personalized treatment decisions.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2025